N/A
N=49
X-ray Dose Reduction Study for Cardiac Angiography and Intervention
Vascular Diseases
Bottom Line
View on ClinicalTrials.gov: NCT01684826 ↗Enrolled (actual)
49
Serious AEs
4.1%
Results posted
Nov 2013
Primary outcome: Primary: Image Quality — 0.85 proportion of readers
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Angiographic run with new algorithm and low dose (50% dose) (Radiation); Angiographic run with predecessor algorithm and dose (100%) (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Philips Clinical & Medical Affairs Global
- Primary completion
- Nov 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Image Quality |
0.85 | — |
| SECONDARY Radiation Dose Measurements: Dose Area Product (DAP) |
-52 | — |
Summary
ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.
Eligibility Criteria
Inclusion Criteria
- Patients older than 18 years of age undergoing coronary angiography
Exclusion Criteria
- Patients not willing or unable to give consent to participate
- Patients already involved in a clinical trial
- Patients under the age of 18
- Pregnant women and breastfeeding women
- Patients with severe kidney disease (eGFR < 60)
Data sourced from ClinicalTrials.gov (NCT01684826). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.